Arab Drug has been growing earnings at an average annual rate of 17%, while the Pharmaceuticals industry saw earnings growing at 21.4% annually. Revenues have been growing at an average rate of 18.8% per year. Arab Drug's return on equity is 41%, and it has net margins of 18.3%.
Key information
17.03%
Earnings growth rate
22.20%
EPS growth rate
Pharmaceuticals Industry Growth
9.80%
Revenue growth rate
18.81%
Return on equity
40.95%
Net Margin
18.28%
Last Earnings Update
31 Dec 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Arab Drug makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
CASE:ADCI Revenue, expenses and earnings (EGP Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
1,234
226
113
0
30 Sep 25
1,191
223
119
0
30 Jun 25
1,118
199
118
0
31 Mar 25
1,026
159
115
0
31 Dec 24
930
123
112
0
30 Sep 24
828
92
102
0
30 Jun 24
786
88
98
0
31 Mar 24
730
70
98
0
31 Dec 23
723
74
97
0
30 Sep 23
671
62
97
0
30 Jun 23
634
71
99
0
31 Dec 22
549
80
91
0
30 Sep 22
515
78
84
0
30 Jun 22
505
76
81
0
31 Dec 21
526
93
82
0
30 Sep 21
532
96
83
0
30 Jun 21
537
101
82
0
31 Mar 21
527
104
76
0
31 Dec 20
540
106
76
0
30 Sep 20
544
106
75
0
30 Jun 20
521
93
73
0
31 Mar 20
524
82
75
0
31 Dec 19
494
66
71
0
30 Sep 19
456
52
69
0
30 Jun 19
436
43
66
0
31 Mar 19
415
43
90
0
31 Dec 18
403
43
91
0
30 Sep 18
401
42
68
0
30 Jun 18
383
39
60
0
31 Mar 18
379
45
20
0
31 Dec 17
371
43
9
0
30 Sep 17
358
39
23
0
30 Jun 17
339
35
22
0
31 Mar 17
315
28
24
0
31 Dec 16
290
22
24
0
30 Sep 16
262
17
25
0
30 Jun 16
250
14
25
0
31 Mar 16
240
6
24
0
31 Dec 15
231
5
23
0
30 Sep 15
225
5
22
0
30 Jun 15
224
5
22
0
Quality Earnings: ADCI has high quality earnings.
Growing Profit Margin: ADCI's current net profit margins (18.3%) are higher than last year (13.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ADCI's earnings have grown by 17% per year over the past 5 years.
Accelerating Growth: ADCI's earnings growth over the past year (83.4%) exceeds its 5-year average (17% per year).
Earnings vs Industry: ADCI earnings growth over the past year (83.4%) exceeded the Pharmaceuticals industry 31.6%.
Return on Equity
High ROE: ADCI's Return on Equity (41%) is considered outstanding.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/17 19:19
End of Day Share Price
2026/05/17 00:00
Earnings
2025/12/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
The Arab Drug Company is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.